USP10 and lung carcinoma: Finally, as the current landscape for the treatment of advanced lung cancer has shifted towards anti-PD-l/PD-L1-based immunotherapy [36], further investigations to connect the USP10-HDAC6 axis to immunotherapy are certainly warranted.